Achromatism represents one of the most profound anomalies in visual science, describing a perceptual reality entirely devoid of chromatic sensation where the world unfolds exclusively in gradations of light, shadow, and luminance. Rather than experiencing the rich tapestry of spectral wavelengths that define standard trichromatic vision, individuals with this condition navigate an environment rendered strictly in monochromatic tones. Understanding achromatism illuminates not only the genetic and neurological architecture of visual processing but also the profound adaptability of human perception in reconstructing form, depth, and spatial coherence without color information.
Achromatism
1. Concise Definition
Achromatism, within visual neuroscience and sensory psychology, is the complete inability to perceive color, resulting in vision that is mediated exclusively through variations in brightness and grayscale contrast. In physical and physiological optics, the term also denotes the property of an optical system or biological lens to transmit light without dispersing it into constituent spectral colors, thereby eliminating chromatic aberration. In clinical neuropsychology and ophthalmology, achromatism is frequently used interchangeably with complete achromatopsia, characterizing an absolute loss or congenital absence of functional cone photoreceptor systems or higher-order cortical color processing centers.
Beyond its sensory definition, achromatism represents a critical model for parsing the modularity of the human visual system. Individuals manifesting complete visual achromatism do not merely possess diminished hue discrimination; rather, they lack the neurobiological apparatus required to translate differing wavelengths of electromagnetic radiation into qualitative color experiences, known philosophically as color qualia. Consequently, spatial visual performance relies entirely upon rod photoreceptors or preserved monochromatic luminance channels, altering fundamental visual parameters including visual acuity, spatial contrast sensitivity, and dark adaptation.
2. Etymology & Linguistic Origin
The term achromatism derives from Classical Greek linguistic roots. It is constructed from the privative prefix a- (ἀ-), signifying “without,” “lacking,” or “absence of,” joined with the noun chroma (χρῶμα), meaning “color,” “tint,” or “complexion.” The noun is completed by the suffix -ism (from the Greek -ismos, -ισμός), designating a particular state, condition, principle, or biological characteristic. Thus, the literal etymological formulation translates precisely to “the condition of being devoid of color.”
The concept entered modern scientific discourse during the late eighteenth and early nineteenth centuries. It initially gained prominence in physical optics following John Dollond’s development of the achromatic doublet lens in 1758, which counteracted chromatic dispersion. By the mid-nineteenth century, as physiological optics emerged through the pioneering works of Hermann von Helmholtz and Thomas Young, medical clinicians and sensory physiologists appropriated the term to describe patients presenting with complete absence of color perception, establishing its enduring foundation in sensory psychology and ophthalmology.
3. Pronunciation & Grammatical Form
In standard academic English, achromatism is pronounced phonetically as /eɪˈkroʊ.məˌtɪz.əm/ in General American phonology and /əˈkrəʊ.məˌtɪz.əm/ in British Received Pronunciation. The primary lexical stress falls on the second syllable (-chro-), with a secondary stress on the fourth syllable.
Grammatically, the word operates as an uncountable abstract noun. Common morphological derivatives and variants include:
- Achromatic (adjective): Relating to, exhibiting, or characterized by the absence of color (e.g., “achromatic vision,” “achromatic lens”).
- Achromatize (transitive verb): To deprive of color or to correct an optical system so that it produces images free from colored fringes.
- Achromat (noun): A person diagnosed with total absence of color vision, or an optical lens system designed to minimize chromatic aberration.
- Achromatopsia (noun): The specific clinical and medical designation for visual pathology characterized by complete or partial loss of color perception.
4. Detailed Conceptual Explanation
To fully grasp achromatism, one must examine the biophysical divergence between physical electromagnetic radiation and subjective color perception. Natural sunlight contains a continuous spectrum of wavelengths spanning roughly 380 to 750 nanometers. Under typical human trichromacy, the retinal neuroepithelium deploys three distinct populations of cone photoreceptors, categorized by their spectral sensitivities: short-wavelength (S-cones, peaking around 420 nm), medium-wavelength (M-cones, peaking around 530 nm), and long-wavelength (L-cones, peaking around 560 nm). The brain processes color by comparing the relative rates of photon capture across these three cone classes via opponent-process pathways. In visual achromatism, this comparative calculation completely collapses.
The condition typically manifests through two distinct etiologies: congenital (retinal) and acquired (cerebral). Congenital achromatism, historically termed rod monochromacy, occurs when genetic mutations disrupt the phototransduction cascade inside cone photoreceptors. With all three cone types nonfunctional or severely compromised, visual processing shifts entirely to rod photoreceptors. Because rods synthesize only a single photopigment—rhodopsin, with peak absorption at approximately 498 nm—the visual system is incapable of discriminating differences in wavelength from differences in light intensity. Every visual input is interpreted along a unidimensional axis of radiant flux, producing a perceptual phenomenology restricted entirely to white, black, and shades of gray.
In contrast, cerebral achromatism arises from acquired neurological trauma, cerebrovascular accident, or localized neoplastic lesions within the ventral occipitotemporal cortex, specifically implicating the lingual and fusiform gyri (human visual area V4 or V4α). In these cases, the peripheral retinal architecture and the primary visual cortex (V1) remain completely intact and capable of registering wavelength differences, but the cerebral processing modules necessary to synthesize chromatic information into conscious perceptual qualia are selectively destroyed. Patients experiencing cerebral achromatism often describe the subjective catastrophe of waking up to a world that resembles an overexposed, tarnished black-and-white photograph.
Furthermore, because the retina’s fovea centralis is densely packed with cones and entirely devoid of rods under normal anatomical conditions, congenital achromatism entails substantial secondary deficits. The reliance on the rod system causes profound central scotomas, severely reduced visual acuity (typically ranging from 20/200 to 20/400), involuntary oscillatory eye movements (nystagmus), and intense photophobia (hebetude of vision in daylight). In bright illumination, the rod photopigments bleach entirely, leaving the individual functionally blinded unless shielded by specialized tinted optical filters.
5. Historical Development
The scientific conceptualization of achromatism unfolded across parallel tracks in physical optics and clinical sensory physiology. In the eighteenth century, Sir Isaac Newton believed that refraction without color dispersion was physically impossible. This premise was overturned in 1758 when British optician John Dollond patented the achromatic lens doublet, demonstrating that combining crown glass and flint glass could cancel out chromatic dispersion. This optical breakthrough permanently cemented the concept of “achromatism” within physical science.
The transition of achromatism into visual physiology gained momentum through early case reports in the nineteenth century. While John Dalton documented his own hereditary red-green color blindness in 1798 (now known as deuteranopia), physicians soon identified far rarer cases of patients who perceived no color whatsoever. In 1877, Swiss ophthalmologist Louis Verrey provided the earliest documented post-mortem anatomical confirmation of acquired cerebral achromatopsia. Verrey documented a female patient who, following an apoplectic stroke affecting the left occipital lobe, lost color vision completely across her right homonymous visual field while maintaining preserved reading ability and visual form perception.
Throughout the twentieth century, the neurobiological basis of achromatism was systematically elucidated. The dual-retina theory pioneered by Max Schultze in 1866 and expanded by Johannes von Kries gained biochemical validation with the discovery of rod and cone phototransduction enzymes. In the 1970s and 1980s, British neurobiologist Semir Zeki conducted seminal electrophysiological studies in primates, identifying area V4 in the visual cortex as a critical hub dedicated to processing color constancy and chromatic boundaries. Concurrently, neurological case studies championed by Oliver Sacks—notably his profile of “The Colorblind Painter” Jonathan I. in An Anthropologist on Mars—popularized the profound cognitive and psychological dimensions of cortical achromatism, while his field research on the Micronesian atoll of Pingelap highlighted the genetic dynamics of hereditary rod monochromacy.
6. Theoretical Foundations
Achromatism provides critical empirical testing grounds for foundational theories of visual perception and cognitive neuroscience. Foremost among these is the Young-Helmholtz trichromatic theory, which posited that human color perception relies on three distinct receptors tuned to short, medium, and long wavelengths. Congenital complete achromatism provides ultimate support for this framework: when the functional integrity of these three receptor mechanisms is genetically eliminated, the entire capacity for wavelength discrimination dissolves, demonstrating that trichromatic receptor input is non-negotiable for human color perception.
Simultaneously, achromatism interfaces directly with Ewald Hering’s opponent-process theory of color vision. Hering argued that visual signals are processed through three antagonistic neurological channels: red versus green, blue versus yellow, and black versus white (achromatic luminance). In achromatism, the two chromatic opponent channels are functionally silent. The visual system operates strictly through the achromatic luminance channel. This physiological dissociation confirms that the luminance channel operates autonomously from chromatic pathways, processing edge detection, luminance contrast, and motion vectors even when hue processing is eliminated.
Within modern cognitive neuroscience, achromatism serves as foundational evidence for the modularity of mind and the functional specialization of the primate visual cortex. Under the visual processing framework formulated by David Marr and expanded by Leslie Ungerleider and Mortimer Mishkin, visual analysis diverges into two anatomical streams: the dorsal (“where” or “how”) stream and the ventral (“what”) stream. Color processing operates as a specialized sub-module embedded within the ventral occipitotemporal pathway. The existence of pure cerebral achromatism—in which an individual retains normal visual acuity, stereoscopic depth perception, and motion detection while losing color—serves as double-dissociation proof that color perception is an independent, modular neurocomputational process rather than a mere secondary property of spatial luminance analysis.
7. Key Components, Types & Dimensions
Achromatism is not a monolithic clinical entity; it is categorized into distinct subtypes based on genetic etiology, anatomical site of impairment, and functional severity:
- Complete Congenital Achromatopsia (Rod Monochromacy): An autosomal recessive retinal disorder characterized by the complete functional loss of all three cone photoreceptor classes. Pathological hallmarks include absolute color blindness, photophobia, low visual acuity, pendular nystagmus, and visual reliance solely on scotopic rod pathways.
- Incomplete Congenital Achromatopsia: A phenotypic variant where residual cone function persists (frequently involving sparse functional S-cones or sub-functional L/M cones). Patients retain minimal color discrimination capabilities, slightly superior visual acuity, and less incapacitating photophobia than seen in complete forms.
- Cerebral Achromatopsia: An acquired neurological condition resulting from focal damage to the ventral visual cortex (lingual and fusiform gyri, human area V4). Retinal cone photoreceptors and the lateral geniculate nucleus function normally, but the brain cannot generate chromatic percepts.
- Hemiachromatopsia: A specialized form of cerebral achromatopsia where cortical damage is restricted to a single cerebral hemisphere. This produces a loss of color vision confined exclusively to the contralateral half of the visual field, while the ipsilateral hemifield preserves full trichromatic vision.
- Transient Achromatopsia: Temporary loss of color perception triggered by acute visual aura during classic migraine, focal epileptic seizures within occipitotemporal circuits, or reversible transient ischemic attacks (TIAs).
- Optical Achromatism: An optical engineering metric denoting a lens system designed with different refractive glasses to bring two distinct wavelengths (typically red and blue) into a shared focal plane, thereby neutralizing chromatic dispersion.
8. Examples & Illustrative Cases
To conceptualize the experiential and clinical realities of achromatism, several real-world examples and documented case studies provide compelling clarity:
Case 1: The Island of the Colorblind (Pingelap Atoll). In the late eighteenth century, a catastrophic typhoon devastated the Micronesian island of Pingelap, leaving roughly twenty survivors. One survivor, the island’s ruler, carried an autosomal recessive mutation in the CNGB3 gene. Due to centuries of geographic and cultural isolation, extreme genetic drift and endogamy elevated the carrier frequency exponentially. Today, nearly 10% of the native population suffers from complete congenital achromatopsia (locally referred to as maskun, meaning “not see”). In bright tropical sunlight, the affected islanders squint and struggle with severe photophobia, but at dusk and night, their rod-dominated vision grants them remarkable night-vision capabilities, allowing them to excel at locating and spearing nocturnal marine life.
Case 2: Cerebral Achromatopsia in an Artist. Documented by neurologist Oliver Sacks and vision researcher Robert Wasserman, Jonathan I., a professional abstract artist, suffered an automobile accident that resulted in closed head trauma. While his visual acuity remained 20/20, he woke to find his psychological world stripped of all hue. His wife’s skin appeared a ghastly rat-gray, tomatoes looked black, and his own paintings were incomprehensible messes of muddy gray tones. Notably, his mnemonic recall of color was also wiped out: he could no longer conceptualize or dream in color, demonstrating that the cortical visual areas responsible for active color processing (V4/V4α) are equally essential for the internal neurological generation of chromatic mental imagery.
Case 3: Incomplete Achromatopsia in Clinical Practice. A pediatric patient presents with developmental nystagmus and severe aversion to bright classroom lighting. Diagnostic electroretinography reveals complete absence of photopic cone responses, but specialized color vision assessment reveals marginal blue-yellow hue discrimination along the tritan axis. Genetic sequencing identifies compound heterozygous mutations within the GNAT2 gene, confirming incomplete achromatopsia. The application of red-tinted contact lenses dramatically mitigates retinal bleaching, stabilizing the child’s gaze and allowing successful mainstream educational integration.
9. Measurement & Assessment
The clinical assessment and diagnostic confirmation of achromatism require comprehensive psychophysical, electrophysiological, and genetic methodologies to differentiate peripheral retinal pathology from central cortical lesions:
Psychophysical testing begins with standardized pseudoisochromatic plates, notably the Ishihara test and Hardy-Rand-Rittler (HRR) plates. While trichromats easily trace chromatic numerals embedded within luminance-matched distractor dots, individuals with complete achromatism fail all chromatic plates, identifying only control plates that rely strictly on luminance contrast. To quantify chromatic discrimination rigorously, clinicians deploy the Farnsworth-Munsell 100 Hue Test or the Farnsworth D-15 arrangement test. Achromats align colored caps entirely according to perceived grayscale reflectance, generating characteristic chaotic error patterns spanning all spectral axes.
Definitive confirmation of congenital achromatism relies on electroretinography (ERG), conducted in accordance with standards set by the International Society for Clinical Electrophysiology of Vision (ISCEV). In complete rod monochromats, the photopic (cone-driven) single-flash and 30-Hz flicker ERG responses are completely flat and extinguished. Conversely, following prolonged dark adaptation, the scotopic (rod-driven) response appears completely robust and normal, demonstrating that the visual pathology is confined strictly to the cone system.
When cerebral achromatopsia is suspected—particularly in patients with sudden color vision loss who show preserved ERG responses—neuroimaging is essential. High-resolution structural magnetic resonance imaging (MRI) and functional MRI (fMRI) are utilized to identify ischemia, infarction, or microvascular hemorrhages within the lingual gyrus, fusiform gyrus, or collateral sulcus of the occipitotemporal cortex. Finally, modern clinical diagnostics employ targeted genomic sequencing panels to isolate pathogenic mutations in six verified genes linked to congenital forms: CNGA3, CNGB3, GNAT2, PDE6C, PDE6H, and ATF6.
10. Applications & Practical Significance
The study and clinical management of achromatism yield profound applications spanning ophthalmology, neuro-rehabilitation, ergonomic design, and sensory engineering:
In clinical low-vision rehabilitation, understanding the pathophysiology of rod monochromacy has spurred innovative assistive technologies. Because rods are rapidly incapacitated by high-intensity light due to rhodopsin saturation, patients require customized optical filters. Red-tinted spectacles or contact lenses serve a crucial therapeutic function: because rhodopsin is minimally sensitive to long wavelengths beyond 650 nm, red filters permit visual navigation without triggering the catastrophic photopic bleaching of the rod network. These filters alleviate photophobia, attenuate nystagmus, and optimize functional contrast sensitivity outdoors.
Within cognitive neuroscience and psychology, achromatism provides vital clinical benchmarks for researching visual awareness and neuroplasticity. Functional imaging of cerebral achromats provides an exceptional template for studying how the brain binds independent visual streams—such as form, motion, and depth—into a single perceptual object without the unifying attribute of color. Furthermore, research into achromatism informs the human-factors engineering of digital user interfaces, driving universal accessibility guidelines (such as the Web Content Accessibility Guidelines, WCAG) to ensure that graphical digital information is never communicated via color distinctions alone.
Perhaps the most cutting-edge application lies in the field of translational gene therapy. Congenital achromatopsia caused by CNGA3 and CNGB3 mutations has emerged as a premier target for recombinant adeno-associated virus (AAV) vector-mediated retinal gene therapy. Clinical trials involving subretinal delivery of functional gene copies demonstrate that adult human neurocircuits retain latent neuroplastic capacity: previously silent cone pathways can be stimulated to convey visual signals decades after birth, establishing a new frontier in reversing congenital sensory blindness.
11. Research & Empirical Evidence
Empirical investigation into achromatism spans decades of foundational molecular genetics, cellular neurobiology, and cognitive neuroscience:
Genetic discovery achieved a critical milestone through the collaborative efforts of Kohl, Wissinger, and colleagues (1998, 2000), who isolated pathogenic mutations in the alpha and beta subunits of the cone cyclic nucleotide-gated (CNG) cation channel, encoded by CNGA3 and CNGB3 respectively. Their molecular research demonstrated that disruption of these subunits arrests the cone phototransduction cascade, preventing hyperpolarization upon photon absorption. Subsequent studies by Chang et al. (2006) revealed that mutations in PDE6C, which encodes the cone alpha-prime subunit of cGMP phosphodiesterase, lead to progressive cone cell death due to toxic cellular cGMP accumulation.
In cortical visual neuroscience, the landmark investigations of Semir Zeki demonstrated that human visual area V4 acts as an essential cortical locus for color construction. Using early positron emission tomography (PET) and functional MRI, Zeki and colleagues showed that cerebral achromatopsia results directly from focal disruption of this area, confirming that the brain actively computes color constancy and chromatic perception rather than passively reflecting retinal inputs. When V4 is damaged, the ability to calculate wavelength ratios across borders disappears, leaving the dorsal and early ventral pathways to perceive luminance devoid of hue.
Recent breakthroughs focus on human gene augmentation trials. In 2020, Fischer and colleagues published results from the first human clinical trial targeting CNGA3-linked achromatopsia using subretinal AAV vector injections. The trial confirmed acceptable safety profiles and documented statistically significant improvements in spatial visual acuity, contrast discrimination, and chromatic threshold detection. Longitudinal neuroimaging by McKyton et al. (2021) demonstrated corresponding reorganization within the visual cortex of treated patients, verifying that long-deprived cortical color circuits can awaken and process cone-mediated signals well past canonical early-childhood critical periods.
12. Cultural & Cross-Cultural Considerations
The sociocultural experience of achromatism varies radically based on geographic prevalence, ecological context, and community awareness. In mainstream industrialized societies, achromatism is an exceptionally rare visual disability (affecting approximately 1 in 30,000 individuals). In these settings, individuals frequently experience social isolation, misunderstanding, and severe academic hurdles, particularly in early childhood where instructional curricula rely heavily on color-coded didactic materials.
Conversely, in geographically isolated enclaves with high genetic prevalence, such as the Pingelap atoll in Micronesia, cultural integration takes a drastically different trajectory. As detailed by Oliver Sacks in his anthropological and scientific explorations, the high prevalence of achromats on the island normalized the condition within the local culture. The community established social structures that accommodate affected individuals, designating them as invaluable nocturnal fishermen due to their extraordinary visual acuity and motion sensitivity in starlight and low-light environments. Far from being viewed through a framework of deficiency, their unique sensory configuration is embraced as an ecological adaptation.
Cross-cultural linguistic research also draws insights from achromatism. The Sapir-Whorf hypothesis and studies by Eleanor Rosch into the linguistic categorization of color reveal how languages structure basic color terms. For an individual with complete achromatism, color vocabulary remains purely abstract and semantic. Studies assessing semantic memory in congenital achromats confirm that they can verbally categorize objects by their socially agreed-upon colors (e.g., knowing that bananas are “yellow” and grass is “green”) purely through cultural linguistic transmission, despite having never experienced the subjective sensory qualia underlying those linguistic tokens.
13. Criticisms, Debates & Limitations
Despite advances in our comprehension of achromatism, several persistent debates and diagnostic ambiguities remain active within visual neuroscience:
A significant theoretical controversy surrounds the functional architecture of area V4 in cerebral achromatism. While early visual modularity models posited that V4 represents an exclusive “color center,” subsequent electrophysiological and neuroimaging studies have revealed that primate V4 also encodes form, spatial orientation, texture, and stereoscopic depth. Critics argue that characterizing V4 strictly as a color module oversimplifies a complex multimodal processing network. Consequently, patients with cerebral achromatopsia frequently exhibit subtle, subclinical impairments in shape-from-shading and face recognition (prosopagnosia), indicating that cortical damage rarely isolates color processing with absolute purity.
Another contentious issue involves the diagnostic terminology surrounding partial versus complete forms. The term achromatopsia is occasionally conflated with severe dyschromatopsia (such as extreme protanopia or deuteranopia). Sensory physiologists emphasize that true achromatism requires the total, unequivocal absence of chromatic opponent channels. Mislabeling severe anomalous trichromats or dichromats as “achromats” leads to clinical mischaracterization and skews visual research cohorts.
In translational medicine, ongoing debate centers on the realistic efficacy and developmental limits of retinal gene therapy. While animal models (such as canine and ovine models of achromatopsia) exhibited dramatic post-treatment restoration of cone vision, human trials reveal more modest visual gains. Researchers actively debate whether visual plasticity in the human brain is sufficiently robust beyond childhood to fully integrate chromatic inputs, or whether enduring amblyopia—caused by decades of cortical deprivation—imposes a ceiling on functional recovery in adult patients.
14. Related Terms & Distinctions
To avoid conceptual ambiguity, achromatism must be carefully distinguished from allied visual and ophthalmologic constructs:
- Achromatopsia vs. Dyschromatopsia: Dyschromatopsia refers to any qualitative deficiency or impairment in color discrimination (including red-green dichromacy such as protanopia or deuteranopia). Achromatopsia/achromatism is the complete and absolute absence of all color perception.
- Congenital Achromatopsia vs. Cerebral Achromatopsia: Congenital achromatopsia stems from genetic mutations abolishing cone photoreceptor function in the retina, co-occurring with low acuity, nystagmus, and photophobia. Cerebral achromatopsia stems from acquired cortical lesions in the ventral occipitotemporal cortex (V4), typically presenting with normal visual acuity and no photophobia or nystagmus.
- Achromatism vs. Chromatic Aberration: Achromatism in optics describes the state or property of an optical system wherein dispersion is neutralized. Chromatic aberration is the optical defect itself, wherein lenses fail to focus all colors onto the same convergence point due to differing refractive indices.
- Achromatism vs. Agnosia (Color Agnosia): Patients with color agnosia can visually discriminate between different hues normally (passing matching tests), but they cannot identify, name, or comprehend the semantic significance of colors due to disrupted connections between visual perception and semantic language centers. Achromats cannot discriminate between hues at all.
- Scotopic Vision vs. Photopic Vision: Scotopic vision is monochromatic vision mediated entirely by rod photoreceptors under low-illumination conditions. Photopic vision is color vision mediated by cone photoreceptors under daylight conditions. Congenital complete achromats are permanently restricted to scotopic-like mechanisms, regardless of ambient luminance levels.
15. Summary / Key Takeaways
Achromatism represents the absolute limit of color vision impairment, manifesting either as an inherited retinal disorder or an acquired cortical injury. In congenital achromatopsia, mutations within genes such as CNGA3 and CNGB3 disable the phototransduction cascade across all three cone photoreceptor populations, forcing total visual reliance upon rod photoreceptors. This condition results in absolute color blindness, severely diminished central visual acuity, involuntary nystagmus, and debilitating daylight photophobia.
Acquired cerebral achromatopsia provides dramatic proof of cortical functional specialization, demonstrating that localized injury to the ventral visual stream—specifically area V4—can eliminate conscious chromatic perception while leaving visual acuity and spatial form vision fully preserved. Beyond its historical impact on the formulation of trichromatic and opponent-process theories, achromatism stands today at the forefront of genetic medicine, where pioneering AAV gene-replacement therapies are actively rewriting the boundaries of sensory recovery and visual neuroplasticity.
In summary, achromatism underscores the profound biological distinction between physical light and perceptual reality. It serves as an enduring testament to the human brain’s capacity to construct a coherent, highly functional spatial universe solely out of the interplay between light, shadow, and luminance.
References
- Fischer, M. D., Michalakis, S., Wilhelm, B., Zobor, D., Muehlfriedel, R., Kohl, S., Weisschuh, N., Ochakovski, G. A., Schmidt, J., Biel, M., & Ueffing, M. (2020). Safety and vision enhancement of gene therapy for CNGA3-achromatopsia: A phase 1/2 clinical trial. JAMA Ophthalmology, 138(6), 643–651. https://doi.org/10.1001/jamaophthalmol.2020.1032
- Kohl, S., Baumann, B., Broghammer, M., Jägle, H., Sieving, P. A., Kellner, U., Spegal, R., Anastasi, M., Zrenner, E., Sharpe, L. T., & Wissinger, B. (2000). Mutations in the CNGB3 gene encoding the beta-subunit of the cone photoreceptor cGMP-gated channel are responsible for achromatopsia (ACHM3) linked to chromosome 8q21. Human Molecular Genetics, 9(14), 2107–2116. https://doi.org/10.1093/hmg/9.14.2107
- Mckyton, A., Ben-Zion, I., Doron, R., & Zohary, E. (2021). Visual restoration after long-term visual deprivation in congenital achromatopsia. Current Biology, 31(15), 3416–3423. https://doi.org/10.1016/j.cub.2021.05.043
- Sacks, O. (1997). The island of the colorblind. Alfred A. Knopf.
- Zeki, S. (1990). A century of cerebral achromatopsia. Brain, 113(6), 1721–1777. https://doi.org/10.1093/brain/113.6.1721